Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of SB16 vs Prolia in Healthy Males
NCT04621318Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of obodence in osteoporosis (3 arms), sponsored by Samsung Bioepis. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity, Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Oct 2020; status: completed.
02
Drugs
obodence
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04621318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621318.